Summary of Study ST001922

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001213. The data can be accessed directly via it's Project DOI: 10.21228/M8X70P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001922
Study TitleSublytic membrane attack complex drives glycolysis and mitochondrial dysfunction with inflammatory consequences in human monocyte-derived macrophages
Study SummaryThe terminal stage in the complement activation pathways, the membrane attack complex (MAC), is upregulated in diabetic and rheumatoid arthritis patients, contributing pathologically by increasing inflammation. Previous research has highlighted that a sublytic dose of MAC can initiate NLRP3 inflammasome activation via calcium influx and loss of mitochondrial membrane potential. Here, we show that sublytic concentrations of MAC mediate a previously undescribed perturbation in cellular energy metabolism in human monocyte-derived macrophages, by phenotypic skewing towards glycolysis and upregulation of glycolysis-promoting genes. Sublytic MAC concentrations drive mitochondrial dysfunction, characterised by a fragmented mitochondrial morphology, loss of maximal respiratory response, depleted mitochondrial membrane potential as well as increased mitochondrial reactive oxygen species production. The consequences of these alterations in glycolytic metabolism and mitochondrial dysfunction lead to NLRP3 inflammasome activation, driving gasdermin D formation and IL-18 release. This novel link between sublytic MAC and immunometabolism, with direct consequences for downstream inflammatory processes, is important for development of novel therapeutics for areas where MAC may mediate disease.
Institute
GSK
DepartmentDiscovery Analytical
LaboratoryMST-MedDesign
Last NameKozole
First NameJoseph
Address1250 Collegeville Ave, Upper Providence, PA, US
Emailjoseph.x.kozole@gsk.com
Phone8144410679
Submit Date2021-09-23
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2021-10-18
Release Version1
Joseph Kozole Joseph Kozole
https://dx.doi.org/10.21228/M8X70P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Collection:

Collection ID:CO001993
Collection Summary:PBMCs were isolated from healthy human blood cones (supplied by GlaxoSmithKlein) by gradient centrifugation. The PBMC layer was collected and monocytes isolated using CD14+ beads (Miltenyi Biotech) according to supplier’s protocol. For proteomics and metabolomics analysis, frozen human primary monocytes were used (supplied by Lonza). Purified monocytes were plated at relevant cell concentration for experiment and treated with growth factor GM-CSF (5 ng/ml) and cultured in RMPI-1640 (Life Technologies) with 5% FCS and 2mM L-glutamine for 6 days, at 37 °C, 5% CO2 to allow differentiation. All human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. On day 6, cells were washed once with treatment media RPMI-1640 with 2mM L-Glutamine and sensitised to complement attack by adding 7 µg/ml of anti-CD55, anti-CD59 and anti-HLA antibodies for 50 min at 37 °C, 5% CO2. Antibody-sensitised cells were exposed to normal human serum (NHS), or non-sensitised cells with NHS alone at 37 °C, 5% CO2 for the indicated amount of time. Subtlytic doses of MAC were characterised as <20% cell death (Campbell, Daw et al. 1979, Reid, Cooke et al. 2012). Alternatively, MAC attack was induced using human purified proteins C5b6-9 for the extracellular H2O2 assay. Cells were incubated with anti-CD59 for 50 min at 37 °C, 5% CO2. Antibody-sensitised cells were exposed to purified protein C5b6 for 10 min at room temperature, followed by addition of purified C7 for 15 min at 37 °C, 5% CO2. C8 and C9 were then added sequentially and left at 37 °C, 5% CO2 for the indicated amount of time. C7, C8 and C9 were added in a molar excess to the C5b6 concentration.
Sample Type:human monocyte-derived macrophages (hMDM)
  logo